<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02943330</url>
  </required_header>
  <id_info>
    <org_study_id>98-2314-B-182-023-MY3</org_study_id>
    <nct_id>NCT02943330</nct_id>
  </id_info>
  <brief_title>Depression, Genes, Cytokines, Chronic Fatigue, Physical Illnesses and Quality of Life</brief_title>
  <official_title>Relation Between Depression, Genes, Cytokines, Chronic Fatigue, Physical Illnesses and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Science Council, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Depression is one of the most common psychiatric diseases, with prevalence estimates ranging
      from 5% to 20%. Depression is now recognized as a brain disease; it can be managed and
      treated effectively with a wide range of options, but its biological basis is still far from
      clear. Studies of monozygotic and dizygotic twin pairs suggest polygenic inheritance, with an
      overall heritability estimate between 40% and 70 %. Gene-environment interaction has been
      recognized for a long time in the pathophysiology of depression, and its best biological
      substratum at present is represented by the serotonin transporter (5-HTT) gene. It would be
      interesting to study association between the novel allelic variants or at least the
      triallelic 5-HTTLPR polymorphism and depression. Depression is common in patients with
      end-stage renal disease and to occur in about 20% to 30% of hemodialysis patients.
      Interferon-induced depression is estimated up to 50% among patients with hepatitis C. Several
      sets of observations support the supposition that cytokines, and proinflammatory cytokines in
      particular, are involved in depressive disorders. Depression sufferers have been reported to
      have elevated blood levels of interleukin 1 (IL-1), IL-6 and tumor necrosis factor α (TNF-α).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to examine the relations between depression and psychiatric family
      history, candidate genes, cytokines and health-related quality of life among hemodialysis
      patients and patients receiving interferon treatment for hepatitis C. The investigators aim
      to recruit 200 hemodialysis patients and 100 patients receiving interferon treatment for
      hepatitis C at Chang Gung Memorial Hospital, Keelung. Our pilot study found that among
      hemodialysis patients, the prevalence rates of probable anxiety disorder and probably
      depression disorder was 25.9% and 40.0%. Among the patients receiving interferon treatment
      for hepatitis C, the prevalence rates of probable anxiety disorder and probably depression
      disorder was 30.2% and 20.7% at baseline, and 44.0% and 36.2% at 3 months after interferon
      treatment. The study procedure consists of 2 parts. For the first one, all the recruited
      hemodialysis patients will receive assessments for fatigue symptoms using Fatigue Scale,
      depressive symptoms using Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg
      Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), blood
      levels of IL-1β, IL-6 and TNF-αas well as psychiatric diagnostic interview with the
      Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic
      Study (FIGS). The second one is a prospective follow up of patients receiving interferon
      treatment. Before initiating interferon treatment, the subjects will receive baseline
      assessments using the same scales mentioned above. The investigators will genotype the
      5-HTTLPR triallelic polymorphism on all subjects. The follow-up visits are at month 1, month
      3, termination, and one month after termination of interferon program. This proposed project
      will provide a broad view and better understanding of the gene-environment interaction in the
      etiology of depression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Psychiatric diagnosis</measure>
    <time_frame>3 years</time_frame>
    <description>Psychiatric diagnosis will be made according to DSM IV criteria after a structured psychiatric diagnosis interview with the Mini-International Neuropsychiatric Interview (MINI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Psychiatric family history</measure>
    <time_frame>3 years</time_frame>
    <description>Psychiatric family history will be obtained by interviewing with the Chinese version of the Diagnostic Interview for Genetic Study. Based on the informant's responses to the general screening questions, five symptom checklists (depression, mania, alcohol and other drug abuse, psychosis, paranoid/schizoid/ schizotypal personality disorder) were completed for each first-degree relative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Anxiety and Depression Scale</measure>
    <time_frame>3 years</time_frame>
    <description>Depressive symptoms will be evaluated using Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS). The HADS is a self-reported scale, and consists of 14 items (7 for anxiety and 7 for depression), which has been frequently applied to assess anxiety and depression symptoms of medically ill patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montgomery Asberg Depression Rating Scale</measure>
    <time_frame>3 years</time_frame>
    <description>The MADRS is a rating scale for severity of depressive mood symptoms. The scale consists of 10 items. Each item is rated from 0 to 6. The MADRS total score is the sum of the 10 items, and the score ranges from 0 to 60.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>Quality of life will be assessed using the Short-form Health-related Quality of Life (SF-36) . This questionnaire assesses eight dimensions of physical and mental health, and the range is from 100 (optimal) to zero (poorest): physical functioning, physical role functioning, bodily pain, general health, vitality, social functioning, emotional role functioning, and mental health.
The SF-36 has demonstrated sensitivity to change, and score changes can be interpreted as changes in the health-related quality of life of the patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue symptoms</measure>
    <time_frame>3 years</time_frame>
    <description>Fatigue symptoms will be evaluated using the self-reported Fatigue Scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines</measure>
    <time_frame>3 years</time_frame>
    <description>The levels of interleukin 1, interleukin 6, tumor necrosis factor α, DHEA, and DHEA-S will be tested via standard ELISA protocol.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genotyping</measure>
    <time_frame>3 years</time_frame>
    <description>The Genomic DNA will be extracted from peripheral blood by standard methods.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">170</enrollment>
  <condition>Hemodialysis</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Hemodialysis</arm_group_label>
    <description>Hemodialysis patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hepatitis C</arm_group_label>
    <description>Patients receiving interferon treatment for hepatitis C</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).</description>
    <arm_group_label>Hemodialysis</arm_group_label>
    <arm_group_label>Hepatitis C</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      IL-1β, IL-6 and TNF-α, as well as genotype the 5-HTTLPR triallelic polymorphism on all
      subjects.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        We aim to recruit 200 demodialysis patients and 100 patients receiving interferon treatment
        for hepatitis C at Chang Gung Memorial Hospital, Keelung.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 years old or more, both males and females

          -  Agree to participate and able to write Informed consent.

        Exclusion Criteria:

          -  No specific exclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chih-Ken Chen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <results_reference>
    <citation>Beck AT, Steer RA, Kovacs M, Garrison B. Hopelessness and eventual suicide: a 10-year prospective study of patients hospitalized with suicidal ideation. Am J Psychiatry. 1985 May;142(5):559-63.</citation>
    <PMID>3985195</PMID>
  </results_reference>
  <results_reference>
    <citation>Cadoret RJ. Evidence for genetic inheritance of primary affective disorder in adoptees. Am J Psychiatry. 1978 Apr;135(4):463-6.</citation>
    <PMID>637144</PMID>
  </results_reference>
  <results_reference>
    <citation>Campi-Azevedo AC, Boson W, De Marco L, Romano-Silva MA, Correa H. Association of the serotonin transporter promoter polymorphism with suicidal behavior. Mol Psychiatry. 2003 Nov;8(11):899-900.</citation>
    <PMID>14593426</PMID>
  </results_reference>
  <results_reference>
    <citation>Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry. 2004 Dec 1;56(11):819-24. Review.</citation>
    <PMID>15576057</PMID>
  </results_reference>
  <results_reference>
    <citation>Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H, McClay J, Mill J, Martin J, Braithwaite A, Poulton R. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science. 2003 Jul 18;301(5631):386-9.</citation>
    <PMID>12869766</PMID>
  </results_reference>
  <results_reference>
    <citation>Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, Wallace EP. Development of a fatigue scale. J Psychosom Res. 1993;37(2):147-53.</citation>
    <PMID>8463991</PMID>
  </results_reference>
  <results_reference>
    <citation>Chen WJ, Liu SK, Chang CJ, Lien YJ, Chang YH, Hwu HG. Sustained attention deficit and schizotypal personality features in nonpsychotic relatives of schizophrenic patients. Am J Psychiatry. 1998 Sep;155(9):1214-20.</citation>
    <PMID>9734545</PMID>
  </results_reference>
  <results_reference>
    <citation>Chisholm D, Sanderson K, Ayuso-Mateos JL, Saxena S. Reducing the global burden of depression: population-level analysis of intervention cost-effectiveness in 14 world regions. Br J Psychiatry. 2004 May;184:393-403. Erratum in: Br J Psychiatry. 2004 Jun;184:546.</citation>
    <PMID>15123502</PMID>
  </results_reference>
  <results_reference>
    <citation>Chou FH, Chou P, Su TT, Ou-Yang WC, Chien IC, Lu MK, Huang MW. Quality of life and related risk factors in a Taiwanese Village population 21 months after an earthquake. Aust N Z J Psychiatry. 2004 May;38(5):358-64.</citation>
    <PMID>15144515</PMID>
  </results_reference>
  <results_reference>
    <citation>Gershon ES, Hamovit J, Guroff JJ, Dibble E, Leckman JF, Sceery W, Targum SD, Nurnberger JI Jr, Goldin LR, Bunney WE Jr. A family study of schizoaffective, bipolar I, bipolar II, unipolar, and normal control probands. Arch Gen Psychiatry. 1982 Oct;39(10):1157-67.</citation>
    <PMID>7125846</PMID>
  </results_reference>
  <results_reference>
    <citation>Goldney RD, Fisher LJ, Wilson DH, Cheok F. Suicidal ideation and health-related quality of life in the community. Med J Aust. 2001 Nov 19;175(10):546-9.</citation>
    <PMID>11795547</PMID>
  </results_reference>
  <results_reference>
    <citation>Heils A, Teufel A, Petri S, Stöber G, Riederer P, Bengel D, Lesch KP. Allelic variation of human serotonin transporter gene expression. J Neurochem. 1996 Jun;66(6):2621-4.</citation>
    <PMID>8632190</PMID>
  </results_reference>
  <results_reference>
    <citation>Hestad KA, Tønseth S, Støen CD, Ueland T, Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT. 2003 Dec;19(4):183-8.</citation>
    <PMID>14657769</PMID>
  </results_reference>
  <results_reference>
    <citation>Horsmans Y. Interferon-induced depression in chronic hepatitis C. J Antimicrob Chemother. 2006 Oct;58(4):711-3. Epub 2006 Sep 2.</citation>
    <PMID>16951413</PMID>
  </results_reference>
  <results_reference>
    <citation>Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, Xu K, Arnold PD, Richter MA, Kennedy JL, Murphy DL, Goldman D. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet. 2006 May;78(5):815-26. Epub 2006 Mar 28.</citation>
    <PMID>16642437</PMID>
  </results_reference>
  <results_reference>
    <citation>Kelley KW, Bluthé RM, Dantzer R, Zhou JH, Shen WH, Johnson RW, Broussard SR. Cytokine-induced sickness behavior. Brain Behav Immun. 2003 Feb;17 Suppl 1:S112-8. Review.</citation>
    <PMID>12615196</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuo CJ, Tang HS, Tsay CJ, Lin SK, Hu WH, Chen CC. Prevalence of psychiatric disorders among bereaved survivors of a disastrous earthquake in taiwan. Psychiatr Serv. 2003 Feb;54(2):249-51.</citation>
    <PMID>12556609</PMID>
  </results_reference>
  <results_reference>
    <citation>Kuo WH, Gallo JJ, Tien AY. Incidence of suicide ideation and attempts in adults: the 13-year follow-up of a community sample in Baltimore, Maryland. Psychol Med. 2001 Oct;31(7):1181-91.</citation>
    <PMID>11681544</PMID>
  </results_reference>
  <results_reference>
    <citation>Lesch KP, Gutknecht L. Pharmacogenetics of the serotonin transporter. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):1062-73. Review.</citation>
    <PMID>15951088</PMID>
  </results_reference>
  <results_reference>
    <citation>Maes M, Vandoolaeghe E, Ranjan R, Bosmans E, Bergmans R, Desnyder R. Increased serum interleukin-1-receptor-antagonist concentrations in major depression. J Affect Disord. 1995 Dec 24;36(1-2):29-36.</citation>
    <PMID>8988262</PMID>
  </results_reference>
  <results_reference>
    <citation>Mendlewicz J, Rainer JD. Adoption study supporting genetic transmission in manic--depressive illness. Nature. 1977 Jul 28;268(5618):327-9.</citation>
    <PMID>887159</PMID>
  </results_reference>
  <results_reference>
    <citation>Miller DB, O'Callaghan JP. Depression, cytokines, and glial function. Metabolism. 2005 May;54(5 Suppl 1):33-8. Review.</citation>
    <PMID>15877311</PMID>
  </results_reference>
  <results_reference>
    <citation>Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry. 2000 Jan;5(1):32-8.</citation>
    <PMID>10673766</PMID>
  </results_reference>
  <results_reference>
    <citation>Nascimento I, Nardi AE, Valença AM, Lopes FL, Mezzasalma MA, Nascentes R, Zin WA. Psychiatric disorders in asthmatic outpatients. Psychiatry Res. 2002 May 15;110(1):73-80.</citation>
    <PMID>12007595</PMID>
  </results_reference>
  <results_reference>
    <citation>Nurnberger JI Jr, Blehar MC, Kaufmann CA, York-Cooler C, Simpson SG, Harkavy-Friedman J, Severe JB, Malaspina D, Reich T. Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. Arch Gen Psychiatry. 1994 Nov;51(11):849-59; discussion 863-4.</citation>
    <PMID>7944874</PMID>
  </results_reference>
  <results_reference>
    <citation>Perlman RL, Finkelstein FO, Liu L, Roys E, Kiser M, Eisele G, Burrows-Hudson S, Messana JM, Levin N, Rajagopalan S, Port FK, Wolfe RA, Saran R. Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study. Am J Kidney Dis. 2005 Apr;45(4):658-66.</citation>
    <PMID>15806468</PMID>
  </results_reference>
  <results_reference>
    <citation>Pirkis J, Burgess P, Dunt D. Suicidal ideation and suicide attempts among Australian adults. Crisis. 2000;21(1):16-25.</citation>
    <PMID>10793467</PMID>
  </results_reference>
  <results_reference>
    <citation>Ritchie K, Artero S, Beluche I, Ancelin ML, Mann A, Dupuy AM, Malafosse A, Boulenger JP. Prevalence of DSM-IV psychiatric disorder in the French elderly population. Br J Psychiatry. 2004 Feb;184:147-52.</citation>
    <PMID>14754827</PMID>
  </results_reference>
  <results_reference>
    <citation>Sakai K, Nakamura M, Ueno S, Sano A, Sakai N, Shirai Y, Saito N. The silencer activity of the novel human serotonin transporter linked polymorphic regions. Neurosci Lett. 2002 Jul 12;327(1):13-6.</citation>
    <PMID>12098489</PMID>
  </results_reference>
  <results_reference>
    <citation>Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57. Review.</citation>
    <PMID>9881538</PMID>
  </results_reference>
  <results_reference>
    <citation>Simon GE, Von Korff M, Lin E. Clinical and functional outcomes of depression treatment in patients with and without chronic medical illness. Psychol Med. 2005 Feb;35(2):271-9.</citation>
    <PMID>15841684</PMID>
  </results_reference>
  <results_reference>
    <citation>Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry. 2000 Oct;157(10):1552-62.</citation>
    <PMID>11007705</PMID>
  </results_reference>
  <results_reference>
    <citation>Suominen K, Isometsä E, Suokas J, Haukka J, Achte K, Lönnqvist J. Completed suicide after a suicide attempt: a 37-year follow-up study. Am J Psychiatry. 2004 Mar;161(3):562-3.</citation>
    <PMID>14992984</PMID>
  </results_reference>
  <results_reference>
    <citation>Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992 Jun;30(6):473-83.</citation>
    <PMID>1593914</PMID>
  </results_reference>
  <results_reference>
    <citation>Weissman MM, Bland RC, Canino GJ, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lepine JP, Newman SC, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen HU, Yeh EK. Prevalence of suicide ideation and suicide attempts in nine countries. Psychol Med. 1999 Jan;29(1):9-17.</citation>
    <PMID>10077289</PMID>
  </results_reference>
  <results_reference>
    <citation>Weissman MM, Gershon ES, Kidd KK, Prusoff BA, Leckman JF, Dibble E, Hamovit J, Thompson WD, Pauls DL, Guroff JJ. Psychiatric disorders in the relatives of probands with affective disorders. The Yale University--National Institute of Mental Health Collaborative Study. Arch Gen Psychiatry. 1984 Jan;41(1):13-21.</citation>
    <PMID>6691780</PMID>
  </results_reference>
  <results_reference>
    <citation>Wender PH, Kety SS, Rosenthal D, Schulsinger F, Ortmann J, Lunde I. Psychiatric disorders in the biological and adoptive families of adopted individuals with affective disorders. Arch Gen Psychiatry. 1986 Oct;43(10):923-9.</citation>
    <PMID>3753159</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang SC, Kuo PW, Wang JD, Lin MI, Su S. Quality of life and its determinants of hemodialysis patients in Taiwan measured with WHOQOL-BREF(TW). Am J Kidney Dis. 2005 Oct;46(4):635-41.</citation>
    <PMID>16183418</PMID>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>October 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2016</study_first_posted>
  <last_update_submitted>October 23, 2016</last_update_submitted>
  <last_update_submitted_qc>October 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Chih-Ken Chen</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Hemodialysis</keyword>
  <keyword>Interferon treatment</keyword>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

